Please assess the completion status of the following clinical trial:

Trial Title: A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>18 to \<75 years of age~* Non ST-elevation myocardial infarction~* Woman of childbearing potential will be allowed only if using two acceptable methods of contraception~* Body mass index (BMI) \</= 40 kg/m2~Exclusion Criteria:~* Acute ST-elevation myocardial infarction (STEMI)~* Culprit coronary lesion with a total thrombotic occlusion or a lesion requiring the use of distal embolization protection or thrombectomy devices~* Percutaneous coronary intervention (PCI) within the past 72 hours~* Thrombolytic therapy within the past 7 days~* Major surgery within the past 3 months~* History of cerebral vascular disease or stroke in the past 3 months~* Bleeding disorders~* Inadequately controlled severe hypertension~* Prior coronary artery bypass graft (CABG) surgery~* Decompensated heart failure (oedema and/or rale)~* Acute infection at screening or active chronic infection within 3 months prior to PCI~* Patients known to be HIV positive, patients receiving antiretroviral drugs, or immuno-suppressed patients~* Uncontrolled diabetes mellitus (HbA1C \>10%) at baseline

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- 20 mg/kg RO4905417 before PCI (Type: EXPERIMENTAL): None
- 5 mg/kg RO4905417 before PCI (Type: EXPERIMENTAL): None
- Placebo before PCI (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).